G
Giuseppe Minniti
Researcher at University of Siena
Publications - 219
Citations - 10214
Giuseppe Minniti is an academic researcher from University of Siena. The author has contributed to research in topics: Radiation therapy & Radiosurgery. The author has an hindex of 50, co-authored 189 publications receiving 7617 citations. Previous affiliations of Giuseppe Minniti include Sapienza University of Rome & The Royal Marsden NHS Foundation Trust.
Papers
More filters
Journal ArticleDOI
Radiosurgery for pituitary adenomas
TL;DR: A systematic review of the literature published between 1985 and 2003 on the efficacy of radiosurgery in patients with pituitary adenomas and at least 6 months’ follow-up excluding single case reports and nonpeer-reviewed chapters is presented.
Journal ArticleDOI
Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas.
Marco Losa,Fausto Bogazzi,S. Cannavò,Filippo Ceccato,Lorenzo Curtò,Laura De Marinis,Donato Iacovazzo,Donato Iacovazzo,Giuseppe Lombardi,Giovanna Mantovani,Elena Mazza,Giuseppe Minniti,Maurizio Nizzoli,Michele Reni,Carla Scaroni +14 more
TL;DR: Temozolomide is an additional effective therapeutic option for the treatment of aggressive pituitary tumors and the drug is well tolerated and causes few severe adverse effects.
Journal ArticleDOI
Long-term follow-up results of postoperative radiation therapy for Cushing’s disease
Giuseppe Minniti,Mattia Falchetto Osti,Marie Lise Jaffrain-Rea,Marie Lise Jaffrain-Rea,Vincenzo Esposito,Giampaolo Cantore,Riccardo Maurizi Enrici +6 more
TL;DR: Radiotherapy is effective in the long-term tumour- and hormone hypersecretion control of ACTH-secreting pituitary adenomas, however with a high prevalence of hypopituitarism.
Journal ArticleDOI
Hypofractionated radiotherapy followed by adjuvant chemotherapy with temozolomide in elderly patients with glioblastoma.
Giuseppe Minniti,V. De Sanctis,Roberta Muni,D. Rasio,Gaetano Lanzetta,Alessandro Bozzao,Mattia Falchetto Osti,Maurizio Salvati,Maurizio Valeriani,G. P. Cantore,R. Maurizi Enrici +10 more
TL;DR: Hypofractionated RT followed by temozolomide may provide survival benefit maintaining a good quality of life in elderly patients with GBM and may represent a reasonable therapeutic approach especially in patients with less favourably prognostic factors.
Journal Article
Integrin Inhibitor Cilengitide for the Treatment of Glioblastoma: A Brief Overview of Current Clinical Results
TL;DR: Cilengitide, a cyclized Arg-Gly-Glu(RGD)-containing pentapeptide that selectively blocks activation of the αvβ3 and αv β5 integrins has shown encouraging activity in patients with glioblastoma as single agent, and in association with standard RT and temozolomide.